Logo image of CATX

PERSPECTIVE THERAPEUTICS INC (CATX) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:CATX - US46489V3024 - Common Stock

2.79 USD
+0.04 (+1.45%)
Last: 1/2/2026, 3:54:04 PM
Fundamental Rating

2

Overall CATX gets a fundamental rating of 2 out of 10. We evaluated CATX against 530 industry peers in the Biotechnology industry. The financial health of CATX is average, but there are quite some concerns on its profitability. CATX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CATX had negative earnings in the past year.
CATX had a negative operating cash flow in the past year.
CATX had negative earnings in each of the past 5 years.
In the past 5 years CATX always reported negative operating cash flow.
CATX Yearly Net Income VS EBIT VS OCF VS FCFCATX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CATX has a Return On Assets of -35.89%. This is in the better half of the industry: CATX outperforms 61.89% of its industry peers.
CATX has a Return On Equity of -43.68%. This is in the better half of the industry: CATX outperforms 69.43% of its industry peers.
Industry RankSector Rank
ROA -35.89%
ROE -43.68%
ROIC N/A
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
CATX Yearly ROA, ROE, ROICCATX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CATX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CATX Yearly Profit, Operating, Gross MarginsCATX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

4

2. Health

2.1 Basic Checks

CATX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CATX has more shares outstanding
Compared to 5 years ago, CATX has more shares outstanding
The debt/assets ratio for CATX has been reduced compared to a year ago.
CATX Yearly Shares OutstandingCATX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CATX Yearly Total Debt VS Total AssetsCATX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

CATX has an Altman-Z score of 0.51. This is a bad value and indicates that CATX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CATX (0.51) is better than 62.64% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that CATX is not too dependend on debt financing.
CATX has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 0.51
ROIC/WACCN/A
WACC8.78%
CATX Yearly LT Debt VS Equity VS FCFCATX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 8.66 indicates that CATX has no problem at all paying its short term obligations.
CATX's Current ratio of 8.66 is fine compared to the rest of the industry. CATX outperforms 76.79% of its industry peers.
A Quick Ratio of 8.66 indicates that CATX has no problem at all paying its short term obligations.
CATX has a Quick ratio of 8.66. This is in the better half of the industry: CATX outperforms 76.98% of its industry peers.
Industry RankSector Rank
Current Ratio 8.66
Quick Ratio 8.66
CATX Yearly Current Assets VS Current LiabilitesCATX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 22.45% over the past year.
Looking at the last year, CATX shows a very negative growth in Revenue. The Revenue has decreased by -59.50% in the last year.
Measured over the past years, CATX shows a very negative growth in Revenue. The Revenue has been decreasing by -27.60% on average per year.
EPS 1Y (TTM)22.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
Revenue 1Y (TTM)-59.5%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%-43.36%

3.2 Future

Based on estimates for the next years, CATX will show a decrease in Earnings Per Share. The EPS will decrease by -2.39% on average per year.
CATX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 180.46% yearly.
EPS Next Y-50.76%
EPS Next 2Y-25.94%
EPS Next 3Y-11.94%
EPS Next 5Y-2.39%
Revenue Next Year-18.33%
Revenue Next 2Y-19.35%
Revenue Next 3Y-23.12%
Revenue Next 5Y180.46%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CATX Yearly Revenue VS EstimatesCATX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
CATX Yearly EPS VS EstimatesCATX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CATX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CATX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CATX Price Earnings VS Forward Price EarningsCATX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CATX Per share dataCATX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

CATX's earnings are expected to decrease with -11.94% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.94%
EPS Next 3Y-11.94%

More info and screens

0

5. Dividend

5.1 Amount

CATX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PERSPECTIVE THERAPEUTICS INC

NYSEARCA:CATX (1/2/2026, 3:54:04 PM)

2.79

+0.04 (+1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-15 2025-12-15/amc
Earnings (Next)04-27 2026-04-27
Inst Owners58.58%
Inst Owner Change-1.48%
Ins Owners3.02%
Ins Owner Change0.01%
Market Cap207.41M
Revenue(TTM)1.07M
Net Income(TTM)-105.80M
Analysts82.11
Price Target12.63 (352.69%)
Short Float %13.85%
Short Ratio4.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.32%
Min EPS beat(2)-5.16%
Max EPS beat(2)5.8%
EPS beat(4)3
Avg EPS beat(4)7.22%
Min EPS beat(4)-5.16%
Max EPS beat(4)20.23%
EPS beat(8)6
Avg EPS beat(8)-8.87%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)37.81%
Min Revenue beat(2)-8.46%
Max Revenue beat(2)84.07%
Revenue beat(4)2
Avg Revenue beat(4)50.48%
Min Revenue beat(4)-8.46%
Max Revenue beat(4)132.36%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.77%
PT rev (3m)-8%
EPS NQ rev (1m)1.23%
EPS NQ rev (3m)-8.88%
EPS NY rev (1m)-3.8%
EPS NY rev (3m)-5.03%
Revenue NQ rev (1m)-1.11%
Revenue NQ rev (3m)-2.99%
Revenue NY rev (1m)-3.11%
Revenue NY rev (3m)-0.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 192.94
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-1.33
Fwd EYN/A
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0.01
BVpS3.26
TBVpS2.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.89%
ROE -43.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 760.26%
Cap/Sales 2085.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.66
Quick Ratio 8.66
Altman-Z 0.51
F-Score1
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)856.63%
Cap/Depr(5y)587.66%
Cap/Sales(3y)1275.31%
Cap/Sales(5y)766.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-66.67%
EPS Next Y-50.76%
EPS Next 2Y-25.94%
EPS Next 3Y-11.94%
EPS Next 5Y-2.39%
Revenue 1Y (TTM)-59.5%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%-43.36%
Revenue Next Year-18.33%
Revenue Next 2Y-19.35%
Revenue Next 3Y-23.12%
Revenue Next 5Y180.46%
EBIT growth 1Y-8.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-52.87%
EBIT Next 3Y-12.88%
EBIT Next 5YN/A
FCF growth 1Y-220.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-161.93%
OCF growth 3YN/A
OCF growth 5YN/A

PERSPECTIVE THERAPEUTICS INC / CATX FAQ

Can you provide the ChartMill fundamental rating for PERSPECTIVE THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CATX.


Can you provide the valuation status for PERSPECTIVE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to PERSPECTIVE THERAPEUTICS INC (CATX). This can be considered as Overvalued.


How profitable is PERSPECTIVE THERAPEUTICS INC (CATX) stock?

PERSPECTIVE THERAPEUTICS INC (CATX) has a profitability rating of 1 / 10.


How sustainable is the dividend of PERSPECTIVE THERAPEUTICS INC (CATX) stock?

The dividend rating of PERSPECTIVE THERAPEUTICS INC (CATX) is 0 / 10 and the dividend payout ratio is 0%.